¸®Æ÷Á» µ¶¼Ò·çºñ½Å ½ÃÀå ±Ô¸ð, Á¡À¯À², µ¿Çâ, »ê¾÷ ºÐ¼® º¸°í¼­ : Á¦Á¦º°, Á¦Ç°º°, À¯Çüº°, Åõ¿© °æ·Îº°, ¿ëµµº°, ÃÖÁ¾»ç¿ëÀÚº°, Áö¿ªº° - ½ÃÀå ¿¹Ãø(2025-2034³â)
Liposomal Doxorubicin Market Size, Share, Trends, Industry Analysis Report: By Drug Formulation, Product, Type, Route of Administration, Application, End User, and Region - Market Forecast, 2025-2034
»óǰÄÚµå : 1625376
¸®¼­Ä¡»ç : Polaris Market Research
¹ßÇàÀÏ : 2024³â 12¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 118 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,250 £Ü 6,149,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 5,250 £Ü 7,596,000
PDF (Multi User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ 20¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,250 £Ü 9,043,000
PDF (Enterprise License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

Polaris Market ResearchÀÇ ÃֽŠÁ¶»ç¿¡ µû¸£¸é ¸®Æ÷Á» µ¶¼Ò·çºñ½Å ¼¼°è ½ÃÀå ±Ô¸ð´Â 2034³â±îÁö 23¾ï 8,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ Á¶»ç º¸°í¼­´Â ÇöÀç ½ÃÀå ¿ªÇп¡ ´ëÇÑ ÀÚ¼¼ÇÑ ÀλçÀÌÆ®¿Í ÇâÈÄ ½ÃÀå ¼ºÀå¿¡ ´ëÇÑ ºÐ¼®À» Á¦°øÇÕ´Ï´Ù.

¸®Æ÷Á» µ¶¼Ò·çºñ½Å ½ÃÀåÀº ¾Ï ¹ßº´·ü Áõ°¡¿Í È¿°úÀûÀΠǥÀû Ä¡·áÁ¦¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡·Î ÀÎÇØ Å« ¼ºÀå¼¼¸¦ º¸À̰í ÀÖ½À´Ï´Ù. ±âÁ¸ µ¶¼Ò·çºñ½Å¿¡ ºñÇØ ºÎÀÛ¿ëÀÌ Àû°í Ä¡·á È¿°ú¸¦ ³ôÀÌ´Â Àü´Þ ¸ÞÄ¿´ÏÁòÀÇ °³¼±µµ ½ÃÀå ¼ºÀåÀÇ ¿øµ¿·ÂÀÌ µÇ°í ÀÖ½À´Ï´Ù.

ÀûÀÀÁõ È®´ë¿Í Á¦Çü ±â¼ú °³¼±¿¡ ÁßÁ¡À» µÐ ¿¬±¸°³¹ßÀÌ ÁøÇàµÇ°í ÀÖÀ¸¸ç, ÀÌ´Â ¿¹Ãø ±â°£ µ¿¾È ½ÃÀå¿¡ À¯¸®ÇÑ ±âȸ¸¦ Á¦°øÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¾Ï ºÐ¾ß¿¡¼­ ¸®Æ÷¼Ø ÀǾàǰÀÇ Ã¤Åà Ȯ´ë¿Í ¸ÂÃãÇü ÀÇ·á¿¡ ´ëÇÑ °ü½É Áõ°¡´Â ÇâÈÄ ¸î ³â µ¿¾È ½ÃÀå ¿ªÇÐÀ» Çü¼ºÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. Àü¹ÝÀûÀ¸·Î ¸®Æ÷Á» µ¶¼Ò·çºñ½Å ½ÃÀåÀº ¾à¹°Àü´Þ ½Ã½ºÅÛ ¹× ¾Ï Ä¡·áÀÇ ¹ßÀü°ú ÇÔ²² °ßÁ¶ÇÑ ¼ºÀå¼¼¸¦ À̾ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¸®Æ÷Á» µ¶¼Ò·çºñ½Å ½ÃÀå º¸°í¼­ ÇÏÀ̶óÀÌÆ®

Á¦Çüº°·Î´Â µ¿°á°ÇÁ¶ ºÐ¸» Á¦ÇüÀÌ ¾ÈÁ¤¼º°ú º¸Á¸±â°£ÀÌ ±æ¾î ½ÃÀåÀ» µ¶Á¡Çϰí ÀÖ½À´Ï´Ù.

Á¦Ç°º°·Î´Â ³ôÀº ºê·£µå ÀÎÁöµµ¿Í ´Ù¾çÇÑ ¾Ï Ä¡·á È¿°ú·Î ÀÎÇØ µ¶½Ç Á¦Á¦°¡ ½ÃÀåÀ» ÁÖµµÇϰí ÀÖ½À´Ï´Ù. ¸®Æ÷µ¶½º(Lipodox) ºÎ¹®µµ µ¶½Ç ´ë½Å ºñ¿ë È¿À²ÀûÀÎ ´ë¾ÈÀ¸·Î Àα⸦ ²ø°í ÀÖ½À´Ï´Ù.

¾ÈÆ®¶ó»çÀÌŬ¸°°è Ç×»ýÁ¦ ºÎ¹®Àº ¾Ï ºÐ¾ß¿¡¼­ÀÇ Æø³ÐÀº Àû¿ë ¹üÀ§¿Í È®¸³µÈ ÀÓ»óÀû À¯¿ë¼ºÀ¸·Î ÀÎÇØ ½ÃÀåÀ» ¼±µµÇϰí ÀÖ½À´Ï´Ù.

Åõ¿© °æ·Îº°·Î´Â ºñ°æ±¸ Åõ¿©°¡ ÁÖ·ù¸¦ ÀÌ·ç°í ÀÖÀ¸¸ç, ÀÌ´Â ¾Ï Ä¡·á¿¡¼­ Á÷Á¢ÀûÀ̰í È¿°úÀûÀÎ Åõ¿© ¹æ¹ýÀ» ¹Ý¿µÇϰí ÀÖ½À´Ï´Ù. ±×·¯³ª ÀáÀçÀûÀÎ ÆíÀǼº°ú È¿°ú·Î ÀÎÇØ ´Ù¸¥ Åõ¿© °æ·Î°¡ °ËÅäµÇ°í ÀÖ½À´Ï´Ù.

¿ëµµº°·Î´Â À¯¹æ¾Ï ºÐ¾ß°¡ ³ôÀº ¹ßº´·ü°ú Ä¡·á¹ýÀÇ ¹ßÀüÀ¸·Î ÀÎÇØ °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇϰí ÀÖ½À´Ï´Ù. ¹æ±¤¾Ï, ¸²ÇÁÁ¾ µî ´Ù¸¥ ºÐ¾ßµµ ¼ºÀåÇϰí ÀÖÁö¸¸ ±× ¼Óµµ´Â ´À¸³´Ï´Ù.

¸®Æ÷Á» µ¶¼Ò·çºñ½ÅÀÇ ÁÖ¿ä ÃÖÁ¾»ç¿ëÀÚ´Â º´¿øÀ̸ç, °í±Þ Ä¡·á ÇÁ·ÎÅäÄݰú ȯÀÚ °ü¸® ´É·ÂÀÌ ±× ¿øµ¿·ÂÀÌ µÇ°í ÀÖ½À´Ï´Ù. Àü¹® ¼¾Åʹ ƯÁ¤ ¾Ï Ä¡·á¿¡ ÁßÁ¡À» µÎ±â ¶§¹®¿¡ äÅÃÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù.

ºÏ¹Ì´Â ³ôÀº ¼öÁØÀÇ ÀÇ·á ÀÎÇÁ¶ó¿Í Çõ½ÅÀûÀÎ Ä¡·á¹ý äÅ÷ü·Î ÀÎÇØ Áö¹èÀûÀÎ Áö¿ªÀ¸·Î ºÎ»óÇß½À´Ï´Ù. ¾Æ½Ã¾ÆÅÂÆò¾çÀº ÀÇ·á ÅõÀÚ Áõ°¡¿Í ¾Ï ¹ßº´·ü Áõ°¡¿¡ ÈûÀÔ¾î °¡Àå ³ôÀº ¼ºÀå·üÀ» º¸ÀÌ´Â ½ÃÀåÀÔ´Ï´Ù.

ÀÌ ½ÃÀåÀÇ ÁÖ¿ä ±â¾÷À¸·Î´Â Johnson & Johnson, Lipoxen, Pfizer, Mylan, Teva Pharmaceuticals, Sun Pharmaceutical Industries, Hengrui Medicine, Inovio Pharmaceuticals, Aurobindo Pharma, and Profound Medical. µîÀÌ ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¼Ò°³

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå Á¶»ç ¹æ¹ý

Á¦4Àå ¼¼°èÀÇ ¸®Æ÷Á» µ¶¼Ò·çºñ½Å ½ÃÀå ÀλçÀÌÆ®

Á¦5Àå ¼¼°èÀÇ ¸®Æ÷Á» µ¶¼Ò·çºñ½Å ½ÃÀå : Á¦Á¦º°

Á¦6Àå ¼¼°èÀÇ ¸®Æ÷Á» µ¶¼Ò·çºñ½Å ½ÃÀå : Á¦Ç°º°

Á¦7Àå ¼¼°èÀÇ ¸®Æ÷Á» µ¶¼Ò·çºñ½Å ½ÃÀå : À¯Çüº°

Á¦8Àå ¼¼°èÀÇ ¸®Æ÷Á» µ¶¼Ò·çºñ½Å ½ÃÀå : Åõ¿© °æ·Îº°

Á¦9Àå ¼¼°èÀÇ ¸®Æ÷Á» µ¶¼Ò·çºñ½Å ½ÃÀå : ¿ëµµº°

Á¦10Àå ¼¼°èÀÇ ¸®Æ÷Á» µ¶¼Ò·çºñ½Å ½ÃÀå : ÃÖÁ¾»ç¿ëÀÚº°

Á¦11Àå ¼¼°èÀÇ ¸®Æ÷Á» µ¶¼Ò·çºñ½Å ½ÃÀå : Áö¿ªº°

Á¦12Àå °æÀï ±¸µµ

Á¦13Àå ±â¾÷ °³¿ä

ksm
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

The global liposomal doxorubicin market size is expected to reach USD 2.38 billion by 2034, according to a new study by Polaris Market Research. The report "Liposomal Doxorubicin Market Size, Share, Trends, Industry Analysis Report: By Drug Formulation (Lyophilized Powder and Doxorubicin Injection), Product (Doxil, Lipodox, Myocet, and Others), Type (Anthracycline Antibiotic and Others), Route of Administration (Parenteral and Others), Application (Bladder Cancer, Kaposi Sarcoma, Leukemia, Lymphoma, Breast Cancer, and Others), End User (Hospitals, Homecare, Specialty Centers, and Others), and Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Forecast, 2025-2034" gives a detailed insight into current market dynamics and provides analysis on future market growth.

The liposomal doxorubicin market is experiencing significant growth due to increasing cancer prevalence and the rising demand for effective targeted therapies. The drug's ability to reduce side effects compared to conventional doxorubicin and its improved delivery mechanism that enhances therapeutic efficacy also drive the market growth.

Ongoing research and development, which focuses on expanding indications and improving formulation technologies, is expected to offer lucrative opportunities for the market during the forecast period. Future trends, such as the growing adoption of liposomal drugs in oncology and the emphasis on personalized medicines, are expected to shape the market dynamics in the coming years. Overall, the liposomal doxorubicin market is poised for robust growth as advancements in drug delivery systems and cancer treatment continue to evolve.

Liposomal Doxorubicin Market Report Highlights:

By drug formulation, the lyophilized powder segment dominates the market due to its stability and longer shelf life.

In terms of product, the Doxil segment leads this market, driven by its strong brand recognition and effectiveness in treating various cancers. The Lipodox segment is also gaining traction as a cost-effective alternative to Doxil.

The anthracycline antibiotic segment, by type, leads the market due to its broad application in oncology and established clinical benefits.

By route of administration, the parenteral route is the dominant method, reflecting its direct and effective delivery in cancer treatment. However, alternative routes are being explored for their potential convenience and efficacy.

Based on application, the breast cancer segment holds the largest share due to its high incidence rate and ongoing advancements in treatment options. Other segments, such as bladder cancer and lymphoma, are also growing but at a slower pace.

Hospitals are the primary end users of liposomal doxorubicin, driven by their capacity for advanced treatment protocols and patient management. Specialty Centers are showing increasing adoption due to their focus on specific cancer treatments.

North America is the dominant region due to advanced healthcare infrastructure and high adoption rates of innovative therapies. Asia Pacific is the highest-growing market, propelled by increasing healthcare investments and rising cancer prevalence.

Some of the key companies in the market are Johnson & Johnson, Lipoxen, Pfizer, Mylan, Teva Pharmaceuticals, Sun Pharmaceutical Industries, Hengrui Medicine, Inovio Pharmaceuticals, Aurobindo Pharma, and Profound Medical.

Polaris Market Research has segmented the liposomal doxorubicin market report on the basis of drug formulation, product, type, route of administration, application, end user, and region:

By Drug Formulation Outlook (Revenue - USD Billion, 2020-2034)

By Product Outlook (Revenue - USD Billion, 2020-2034)

By Type Outlook (Revenue - USD Billion, 2020-2034)

By Route of Administration Outlook (Revenue - USD Billion, 2020-2034)

By Application Outlook (Revenue - USD Billion, 2020-2034)

By End User Outlook (Revenue - USD Billion, 2020-2034)

By Regional Outlook (Revenue - USD Billion, 2020-2034)

Table of Contents

1. Introduction

2. Executive Summary

3. Research Methodology

4. Global Liposomal Doxorubicin Market Insights

5. Global Liposomal Doxorubicin Market, by Drug Formulation

6. Global Liposomal Doxorubicin Market, by Product

7. Global Liposomal Doxorubicin Market, by Type

8. Global Liposomal Doxorubicin Market, by Route of Administration

9. Global Liposomal Doxorubicin Market, by Application

10. Global Liposomal Doxorubicin Market, by End User

11. Global Liposomal Doxorubicin Market, by Geography

12. Competitive Landscape

13. Company Profiles

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â